title: Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network.
abstract: Progress has been made in the treatment of metastatic breast cancer in recent decades, but very few therapies use patient or tumor-specific characteristics to tailor individualized treatment. More than ten years after the publication of the reference human genome sequence, analysis methods have improved enormously, fostering the hope that biomarkers can be used to individualize therapies and offer precise treatment based on tumor and patient characteristics. Biomarkers at every level of the system (genetics, epigenetics, gene expression, micro-RNA, proteomics and others) can be used for this. This has led to changes in clinical study designs, with drug developments often only focusing on small or very small subgroups of patients and tumors. The screening and registration of patients and their molecular tumor data has therefore become very important for the successful completion of clinical studies. This new form of medicine presents particular challenges for patients and physicians. Even in this new age of genome-wide analysis, the focus should still be on the patients' quality of life. This review summarizes recent developments and describes how the PRAEGNANT study network manages the aforementioned medical challenges and changes to create a professional infrastructure for patients and physicians.
authors: Frauenklinik des Universitätsklinikums Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen ; Wissenschaftliche Leitung PRAEGNANT-Studiennetzwerk.
authors: P A
authors: PA
authors: Fasching
authors: Forschungsinstitut für Frauengesundheit, Department für Frauengesundheit, Universitätsklinikum Tübingen, Eberhard Karls Universität Tübingen, Tübingen ; Wissenschaftliche Leitung PRAEGNANT-Studiennetzwerk.
authors: S Y
authors: SY
authors: Brucker
authors: Universitäts-Frauenklinik Düsseldorf, Heinrich-Heine Universität Düsseldorf, Düsseldorf.
authors: T N
authors: TN
authors: Fehm
authors: Oncologianova GmbH Recklinghausen, Recklinghausen.
authors: F
authors: F
authors: Overkamp
authors: Universitätsfrauenklinik Ulm, Ulm.
authors: W
authors: W
authors: Janni
authors: Universitätsfrauenklinik Heidelberg, Ruprecht-Karls-Universität Heidelberg, Heidelberg.
authors: M
authors: M
authors: Wallwiener
authors: Krankenhaus Nordwest, Klinik für Gynäkologie und Geburtshilfe, Frankfurt am Main.
authors: P
authors: P
authors: Hadji
authors: Clin-Sol GmbH, Würzburg.
authors: E
authors: E
authors: Belleville
authors: Frauenklinik des Universitätsklinikums Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen ; Unit of Biostatistics, Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen.
authors: L
authors: L
authors: Häberle
authors: Universitäts-Frauenklinik, Department für Frauengesundheit, Universitätsklinikum Tübingen, Eberhard Karls Universität Tübingen, Tübingen.
authors: F-A
authors: FA
authors: Taran
authors: Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie; Charité Campus Benjamin Franklin Berlin, Berlin.
authors: D
authors: D
authors: Lüftner
authors: Frauenklinik des Universitätsklinikums Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen.
authors: M P
authors: MP
authors: Lux
authors: Abteilung Gynäkologie und Geburtshilfe, Klinikum rechts der Isar, Technische Universität München, Munich.
authors: J
authors: J
authors: Ettl
authors: Klinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg.
authors: V
authors: V
authors: Müller
authors: Onkologie Bethanien, Frankfurt am Main ; Studienleitung PRAEGNANT-Studie.
authors: H
authors: H
authors: Tesch
authors: Universitäts-Frauenklinik, Department für Frauengesundheit, Universitätsklinikum Tübingen, Eberhard Karls Universität Tübingen, Tübingen ; Studienleitung PRAEGNANT-Studie.
authors: D
authors: D
authors: Wallwiener
authors: Universitätsfrauenklinik Ulm, Ulm ; Nationales Centrum für Tumorerkrankungen, Heidelberg.
authors: A
authors: A
authors: Schneeweiss
keywords: PRAEGNANT; biomarker; breast cancer; metastasis; mutation; prognosis